Wade G W & Inc. increased its position in shares of Stryker Co. (NYSE:SYK) by 22.2% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,301 shares of the medical technology company’s stock after acquiring an additional 600 shares during the period. Wade G W & Inc.’s holdings in Stryker were worth $688,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently bought and sold shares of SYK. FinTrust Capital Advisors LLC grew its stake in shares of Stryker by 1,924.1% in the 2nd quarter. FinTrust Capital Advisors LLC now owns 1,093 shares of the medical technology company’s stock valued at $197,000 after purchasing an additional 1,039 shares during the last quarter. AE Wealth Management LLC lifted its holdings in shares of Stryker by 31.2% in the 2nd quarter. AE Wealth Management LLC now owns 12,812 shares of the medical technology company’s stock valued at $2,309,000 after buying an additional 3,045 shares during the period. Bailard Inc. lifted its holdings in shares of Stryker by 2.1% in the 2nd quarter. Bailard Inc. now owns 8,666 shares of the medical technology company’s stock valued at $1,562,000 after buying an additional 175 shares during the period. Creative Planning lifted its holdings in shares of Stryker by 2.2% in the 2nd quarter. Creative Planning now owns 36,354 shares of the medical technology company’s stock valued at $6,551,000 after buying an additional 772 shares during the period. Finally, LGT Capital Partners LTD. lifted its holdings in shares of Stryker by 10.3% in the 3rd quarter. LGT Capital Partners LTD. now owns 410,350 shares of the medical technology company’s stock valued at $85,505,000 after buying an additional 38,246 shares during the period. 71.02% of the stock is currently owned by hedge funds and other institutional investors.
Shares of NYSE:SYK opened at $235.78 on Tuesday. The company has a market cap of $88.60 billion, a P/E ratio of 56.00, a P/E/G ratio of 3.71 and a beta of 0.78. The company has a quick ratio of 2.12, a current ratio of 2.91 and a debt-to-equity ratio of 0.93. Stryker Co. has a 52 week low of $124.54 and a 52 week high of $241.53. The business has a fifty day simple moving average of $216.57 and a 200-day simple moving average of $197.84.
Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, October 29th. The medical technology company reported $2.14 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.40 by $0.74. Stryker had a return on equity of 20.53% and a net margin of 11.38%. The firm had revenue of $3.74 billion during the quarter, compared to the consensus estimate of $3.41 billion. During the same quarter in the previous year, the business earned $1.91 earnings per share. The firm’s quarterly revenue was up 4.2% compared to the same quarter last year. Sell-side analysts expect that Stryker Co. will post 6.33 earnings per share for the current fiscal year.
Several research firms have recently commented on SYK. SVB Leerink raised their price target on Stryker from $225.00 to $235.00 and gave the company an “outperform” rating in a report on Friday, October 30th. Raymond James raised their price target on Stryker from $220.00 to $240.00 and gave the company an “outperform” rating in a report on Monday, October 12th. TheStreet raised Stryker from a “c+” rating to a “b+” rating in a report on Thursday, October 29th. Northland Securities began coverage on Stryker in a report on Tuesday, October 6th. They issued a “market perform” rating and a $225.00 price target for the company. Finally, Oppenheimer reaffirmed a “hold” rating and set a $215.00 price objective on shares of Stryker in a report on Friday, July 31st. Three investment analysts have rated the stock with a sell rating, nine have issued a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the stock. Stryker currently has an average rating of “Buy” and a consensus price target of $220.23.
Stryker Company Profile
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices that are used in various medical specialties.
Read More: Trading Strategy
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.